Skip Nav Destination
mTOR inhibition in T-cell lymphoma: a path(way) forward
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma
Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy
Rare and strange invader
Issue Archive
July 16 2015
In this Issue
Table of Contents
INSIDE BLOOD COMMENTARIES
INSIDE BLOOD COMMENTARY
mTOR inhibition in T-cell lymphoma: a path(way) forward
Clinical Trials & Observations
PLENARY PAPER
CLINICAL TRIALS AND OBSERVATIONS
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Clinical Trials & Observations
Hervé Dombret,John F. Seymour,Aleksandra Butrym,Agnieszka Wierzbowska,Dominik Selleslag,Jun Ho Jang,Rajat Kumar,James Cavenagh,Andre C. Schuh,Anna Candoni,Christian Récher,Irwindeep Sandhu,Teresa Bernal del Castillo,Haifa Kathrin Al-Ali,Giovanni Martinelli,Jose Falantes,Richard Noppeney,Richard M. Stone,Mark D. Minden,Heidi McIntyre,Steve Songer,Lela M. Lucy,C. L. Beach,Hartmut Döhner
PERSPECTIVES
REVIEW ARTICLE
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma
Clinical Trials & Observations
Thomas E. Witzig,Craig Reeder,Jing Jing Han,Betsy LaPlant,Mary Stenson,Han W. Tun,William Macon,Stephen M. Ansell,Thomas M. Habermann,David J. Inwards,Ivana N. Micallef,Patrick B. Johnston,Luis F. Porrata,Joseph P. Colgan,Svetomir Markovic,Grzegorz S. Nowakowski,Mamta Gupta
LYMPHOID NEOPLASIA
STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma
Chengsheng Wu,Ommoleila Molavi,Haifeng Zhang,Nidhi Gupta,Abdulraheem Alshareef,Kathleen M. Bone,Keshav Gopal,Fang Wu,Jamie T. Lewis,Donna N. Douglas,Norman M. Kneteman,Raymond Lai
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma
Salvia Jain,Dina Stroopinsky,Li Yin,Jacalyn Rosenblatt,Maroof Alam,Parul Bhargava,Rachael A. Clark,Thomas S. Kupper,Kristen Palmer,Maxwell D. Coll,Hasan Rajabi,Athalia Pyzer,Michal Bar-Natan,Katarina Luptakova,Jon Arnason,Robin Joyce,Donald Kufe,David Avigan
MYELOID NEOPLASIA
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
PLATELETS AND THROMBOPOIESIS
RED CELLS, IRON, AND ERYTHROPOIESIS
The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice
Shuaiying Cui,Kim-Chew Lim,Lihong Shi,Mary Lee,Natee Jearawiriyapaisarn,Greggory Myers,Andrew Campbell,David Harro,Shigeki Iwase,Raymond C. Trievel,Angela Rivers,Joseph DeSimone,Donald Lavelle,Yogen Saunthararajah,James Douglas Engel
THROMBOSIS AND HEMOSTASIS
TRANSFUSION MEDICINE
TRANSPLANTATION
Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy
Clinical Trials & Observations
Yasuyuki Arai,June Takeda,Kazunari Aoki,Tadakazu Kondo,Satoshi Takahashi,Yasushi Onishi,Yukiyasu Ozawa,Nobuyuki Aotsuka,Yasuji Kouzai,Hirohisa Nakamae,Shuichi Ota,Chiaki Nakaseko,Hiroki Yamaguchi,Koji Kato,Yoshiko Atsuta,Akiyoshi Takami,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation,on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation
BLOOD WORK
Rare and strange invader
Clinical Trials & Observations
ERRATA
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
-
Cover Image
Cover Image
![issue cover]()
A representative tumor of ALK-positive anaplastic large-cell lymphoma (ALK+ALCL). The large cells in the figure are ALK+ALCL cells showing negative staining of STAT1. The cells stained in brown are benign lymphocytes and macrophages, which demonstrate strong STAT1 staining. The figure suggests that STAT1 is expressed at a relatively low level in ALK+ALCL compared with its expression in the surrounding benign lymphocytes. See the article by Lai et al on page 336.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
